Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

Overview

• Switzerland-based gene-editing firm's Q3 CASGEVY revenue rose 30% sequentially, nearly six times yr/yr

• Company expanded CASGEVY approvals for younger children in U.K. and Middle East

• Q3 net loss widened to $111.4 mln from $106.4 mln a year ago

Outlook

• Company expects updates from CTX611 Phase 2 trial in H2 2026

• Phase 1b data for CTX310 in severe hypertriglyceridemia to be presented November 2026

• Phase 1 data for zugo-cel in systemic sclerosis to be presented November 2026

Result Drivers

• CASGEVY EXPANSION - Co said Q3 revenue growth was driven by expanded approvals and increased patient access for CASGEVY, including younger children in U.K. and Middle East

• PATIENT INITIATION - Co said more than 750 patients have initiated CASGEVY treatment worldwide, with twice as many in first nine months of 2026 as in all of 2025

• R&D SPEND - Co said increase in Q3 R&D expense was primarily due to higher external research and development expenses and sublicense fees

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

Reuters Recommended Reads

• Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

• Nov 2 - Tiziana's experimental MS treatment meets main goals in mid-stage study

• Nov 2 - Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)